TRIB VS SYBX Stock Comparison

Performance

TRIB
10/100

TRIB returned -60.18% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

SYBX
10/100

SYBX returned -80.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

TRIB
83/100

3 analysts offer 12-month price targets for TRIB. Together, they have an average target of 0, the most optimistic target put TRIB at 0 within 12-months and the most pessimistic has TRIB at 0.

SYBX
100/100

1 analysts offer 12-month price targets for SYBX. Together, they have an average target of 0, the most optimistic target put SYBX at 0 within 12-months and the most pessimistic has SYBX at 0.

Sentiment

TRIB
67/100

TRIB had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 5.22 posts, 3.44 comments, and 2.83 likes per day.

SYBX
78/100

SYBX had a bullish sentiment score of 77.54% across Twitter and StockTwits over the last 12 months. It had an average of 2.27 posts, 0.18 comments, and 0.73 likes per day.

Technicals

TRIB
11/100

TRIB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

SYBX
43/100

SYBX receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

TRIB
10/100

TRIB has missed earnings 10 times in the last 20 quarters.

SYBX
36/100

SYBX has missed earnings 3 times in the last 20 quarters.

Profit

TRIB
48/100

Out of the last 20 quarters, TRIB has had 14 profitable quarters and has increased their profits year over year on 4 of them.

SYBX
10/100

Out of the last 20 quarters, SYBX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

TRIB
50/100

TRIB has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

SYBX
48/100

SYBX has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Trinity Biotech plc Summary

Nasdaq / TRIB

Healthcare

Medical - Diagnostics & Research

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Synlogic, Inc. Common Stock Summary

Nasdaq / SYBX

Healthcare

Biotechnology

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Power up your portfolio